FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
7d
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
Issued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics ...
On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
Scientists from National Taiwan University (NTU) and Linkou Chang Gung Memorial Hospital (CGMH) have developed a ...
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...
Hypertrophic scarring affects a large proportion of patients following burns, trauma, or surgery and arises from prolonged fibroblast hyperactivity and excessive extracellular matrix accumulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results